Stockholm - Delayed Quote ? SEK Alligator Bioscience AB (ATORX-TO-9.ST) Follow Compare 0.0750 -0.0505 (-40.24%) At close: November 6 at 5:14 PM GMT+1 Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for ATORX-TO-9.ST 1D 5D 1M 3M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: ATORX-TO-9.ST View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Alligator Bioscience Presents an Update with Clinical and Biomarker Results with Mitazalimab in Phase 2 Pancreatic Cancer at SITC 2024 ACCESSWIRE ? 16 hours ago Nomination Committee Appointed in Respect of AGM 2025 in Alligator Bioscience AB ACCESSWIRE ? 6 days ago Alligator Bioscience to Participate in Upcoming Scientific and Investor Conferences in Q4 2024 ACCESSWIRE ? 7 days ago Alligator Bioscience and Aptevo Therapeutics to Present Additional Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at SITC 2024 ACCESSWIRE ? 8 days ago Alligator Bioscience AB Reports Financial Results for the First 9 Months of 2024 and for Q3 2024 and Provides a Business Update ACCESSWIRE ? 13 days ago Alligator Bioscience AB (FRA:7AL) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ... GuruFocus.com ? 28 days ago Alligator Bioscience and Aptevo Therapeutics Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study ACCESSWIRE ? last month Alligator Bioscience and Aptevo Therapeutics to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types at ESMO Congress 2024 ACCESSWIRE ? last month Alligator Bioscience AB Reports Financial Results for H1 2024 and Q2 2024 and Provides a Business Update ACCESSWIRE ? 3 months ago Alligator Bioscience Announces Substantial Overall Survival Benefit and Unprecedented Duration of Response in the 18-Month Analysis from Mitazalimab OPTIMIZE-1 Phase 2 Study in 1st Line Pancreatic Cancer ACCESSWIRE ? 4 months ago Alligator Bioscience Announces Financing of Up to SEK 80 Million Extending Cash Runway to Q1 2025 ACCESSWIRE ? 4 months ago View More Related Tickers FLUI.ST Fluicell AB (publ) 0.0706 -1.94% ? COMBI.ST CombiGene AB (publ) 2.6600 +3.91% ? HNSA.ST Hansa Biopharma AB (publ) 32.32 -3.69% ? NEXI NexImmune, Inc. 0.2069 -4.92% ? APVO Aptevo Therapeutics Inc. 0.2580 -3.73% ? TNXP Tonix Pharmaceuticals Holding Corp. 0.1400 -1.34% ?
